UNSPSC 51332859: Mesoridazine besylate

This classification denotes a dopamine antagonist and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4G2I958J2. European Medicines Agency schedules Mesoridazine besilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03180MIG. Mesoridazine besylate generally arises in the molecular formula C21H26N2OS2.C6H6O3S. The term 'mesoridazine besylate' is a U.S. Pharmacopeial Convention designation.

Most nations, for tariff and trade purposes, schedule mesoridazine besylate under HS 29343090. As of Q4 2014, MESORIDAZINE BESYLATE remains US FDA's Preferred Term for this commodity. Mesoridazine besylate bears US NLM identifiers UMLS ID C0700543 and NCI Concept Code C66101. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)[S+](C)[O-].C1CCC(CC1)S(=O)(=O)O.

UNSPSC 51332859 Mesoridazine besylate is a Commodity code that in practice covers pharmaceutical products acquired by state and local health agencies, though recent opportunities tagged to this code show minimal alignment with the specific drug named. State and local governments purchasing under this code acquire generic pharmaceuticals, over-the-counter products, and naloxone through both direct procurement and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies and local government facilities. Work involves vendor qualification, product supply through authorized wholesalers or direct delivery, compliance with FDA and Drug Supply Chain Security Act (DSCSA) requirements, and maintenance of inventory for quarterly or ongoing distribution to county health buildings and state pharmacy benefit programs.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building; the contract includes a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and potential FEMA funding compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured health plans outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 10 percent combined on administrative compliance and EDI capability.